Craft

Amarin

Stock Price

$0.6

2024-10-29

Market Capitalization

$257.6 M

2024-10-29

Revenue

$228.6 M

FY, 2024

Amarin Summary

Company Summary

Overview
Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases. It develops VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Type
Public
Status
Active
Founded
1991
HQ
Dublin, IE | view all locations
Website
https://amarincorp.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Lars G. Ekman
  • Jan van Heek, Non-Executive Director

  • Patrick J. O'Sullivan, Non-Executive Director

    • Kristine Peterson, Non-Executive Director

      Operating MetricsView all

      Patents (US)

      110
      19.6%

      FY, 2020

      Patent Applications (US)

      30

      FY, 2020

      LocationsView all

      3 locations detected

      • Dublin, D HQ

        Ireland

        Block C, 77 Sir John Rogerson's Quay

      • Bridgewater Township, NJ

        United States

        440 Route 22

      • Zug, ZG

        Switzerland

        Grafenauweg 8

      Amarin Financials

      Summary Financials

      Revenue (FY, 2024)
      $228.6M
      Gross profit (FY, 2024)
      $81.4M
      Net income (FY, 2024)
      ($82.2M)
      Cash (FY, 2024)
      $121.0M
      EBIT (FY, 2024)
      ($91.8M)
      Enterprise value
      $138.5M

      Footer menu